Pyxis Oncology, Inc. 发布了2026年第二季度财务业绩,并同步推进其核心候选药物Micvo,向着2026年关键临床里程碑迈进。这家专注于肿瘤领域的生物制药公司,正通过一系列战略举措,强化其管线布局。
Pyxis Oncology, Inc. 发布了2026年第二季度财务业绩,并同步推进其核心候选药物Micvo,向着2026年关键临床里程碑迈进。这家专注于肿瘤领域的生物制药公司,正通过一系列战略举措,强化其管线布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.